| Edwin Benedict Flanagan, DO | |
|
1651 Se Tiffany Ave, Port St Lucie, FL 34952-7564 | |
| (772) 398-1800 | |
| (772) 398-1815 |
| Full Name | Edwin Benedict Flanagan |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 38 Years |
| Location | 1651 Se Tiffany Ave, Port St Lucie, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043239866 | NPI | - | NPPES |
| 370979500 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | OS6311 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic Martin North Hospital | Stuart, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Martin Memorial Physicians Corporation Inc | 7315833555 | 372 |
News Archive
Cardiovascular leaders will gather in Minneapolis for a one-day summit on Jan. 20, to review data for Riata and Riata ST implantable cardioverter-defibrillator (ICD) leads, which recently underwent a Class I FDA recall. Physicians from the Minneapolis Heart Institute Foundation and Mayo Clinic have organized the summit to develop a consensus regarding the management of patients who have these leads.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
A new study published in the journal JAMA Neurology in March 2020 suggests that stress-related disorders increase the risk of later development of dementia and other neurodegenerative disorders.
Australian scientists have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why some patients respond to these drugs, while others do not.
› Verified 3 days ago
| Entity Name | Florida Hospital Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225034234 PECOS PAC ID: 0749186153 Enrollment ID: O20031208000807 |
News Archive
Cardiovascular leaders will gather in Minneapolis for a one-day summit on Jan. 20, to review data for Riata and Riata ST implantable cardioverter-defibrillator (ICD) leads, which recently underwent a Class I FDA recall. Physicians from the Minneapolis Heart Institute Foundation and Mayo Clinic have organized the summit to develop a consensus regarding the management of patients who have these leads.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
A new study published in the journal JAMA Neurology in March 2020 suggests that stress-related disorders increase the risk of later development of dementia and other neurodegenerative disorders.
Australian scientists have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why some patients respond to these drugs, while others do not.
› Verified 3 days ago
| Entity Name | Martin Memorial Physicians Corporation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578505228 PECOS PAC ID: 7315833555 Enrollment ID: O20040225000440 |
News Archive
Cardiovascular leaders will gather in Minneapolis for a one-day summit on Jan. 20, to review data for Riata and Riata ST implantable cardioverter-defibrillator (ICD) leads, which recently underwent a Class I FDA recall. Physicians from the Minneapolis Heart Institute Foundation and Mayo Clinic have organized the summit to develop a consensus regarding the management of patients who have these leads.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
A new study published in the journal JAMA Neurology in March 2020 suggests that stress-related disorders increase the risk of later development of dementia and other neurodegenerative disorders.
Australian scientists have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why some patients respond to these drugs, while others do not.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edwin Benedict Flanagan, DO Po Box 417, Stuart, FL 34995-0417 Ph: (772) 223-5665 | Edwin Benedict Flanagan, DO 1651 Se Tiffany Ave, Port St Lucie, FL 34952-7564 Ph: (772) 398-1800 |
News Archive
Cardiovascular leaders will gather in Minneapolis for a one-day summit on Jan. 20, to review data for Riata and Riata ST implantable cardioverter-defibrillator (ICD) leads, which recently underwent a Class I FDA recall. Physicians from the Minneapolis Heart Institute Foundation and Mayo Clinic have organized the summit to develop a consensus regarding the management of patients who have these leads.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
A new study published in the journal JAMA Neurology in March 2020 suggests that stress-related disorders increase the risk of later development of dementia and other neurodegenerative disorders.
Australian scientists have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why some patients respond to these drugs, while others do not.
› Verified 3 days ago
Dr. Theodore G Pettle, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1700 Se Hillmoor Dr, Port St Lucie, FL 34952 Phone: 772-335-9600 | |
Alan Steven Collin, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 1871 Se Tiffany Ave, Suite 100, Port St Lucie, FL 34952 Phone: 772-335-5666 Fax: 772-335-4826 | |
Dr. Gerald John Rutecki, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 473 Nw Blue Lake Dr, Port St Lucie, FL 34986 Phone: 772-336-8039 | |
Dr. Dana D Dameron Jr., D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 475 Nw Prima Vista Blvd, Port St Lucie, FL 34983 Phone: 772-800-3037 Fax: 772-807-1409 | |
Ahmet Bahadir Ergin, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1700 Se Hillmoor Dr, Port St Lucie, FL 34952 Phone: 772-335-9600 Fax: 772-335-7972 | |
Dr. Philip Lortz, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1855 Se Port St Lucie Blvd, Port St Lucie, FL 34952 Phone: 772-288-6300 Fax: 772-288-6374 |